{"id":"inhaled-corticosteroids-ics","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oral candidiasis (thrush)"},{"rate":"5-10","effect":"Hoarseness"},{"rate":"5-15","effect":"Cough"},{"rate":"null","effect":"Tremor (from beta-agonist co-formulation if applicable)"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Dysphonia"}]},"_chembl":{"chemblId":"CHEMBL556193","moleculeType":"Small molecule","molecularWeight":"334.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ICs work locally in the lungs to inhibit the transcription of pro-inflammatory genes, reducing recruitment and activation of eosinophils, mast cells, and T lymphocytes. This decreases mucus production, airway edema, and bronchial hyperresponsiveness. The inhaled route delivers high local concentrations while minimizing systemic exposure and side effects.","oneSentence":"Inhaled corticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:51.409Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (mild to moderate persistent)"},{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma-COPD overlap syndrome"}]},"trialDetails":[{"nctId":"NCT06372496","phase":"PHASE4","title":"Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-04-16","conditions":"Asthma","enrollment":1366},{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT07073950","phase":"PHASE4","title":"A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Chronic Obstructive Pulmonary Disease, Hyperinflation","enrollment":56},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT05677139","phase":"","title":"A Study for Observing Severe Asthma in Patients Treated With Tezepelumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-12-13","conditions":"Asthma","enrollment":513},{"nctId":"NCT06596512","phase":"NA","title":"Improving the Quality of Care for Asthma Patients at Risk of Exacerbations","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-07","conditions":"Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation","enrollment":4100},{"nctId":"NCT03953300","phase":"PHASE4","title":"Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-08","conditions":"Asthma","enrollment":75},{"nctId":"NCT06419413","phase":"","title":"A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-01-08","conditions":"Asthma","enrollment":355},{"nctId":"NCT02476825","phase":"PHASE4","title":"A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospitals, Leicester","startDate":"2016-01-20","conditions":"Healthy","enrollment":30},{"nctId":"NCT03963167","phase":"","title":"Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2019-08-21","conditions":"COPD","enrollment":661},{"nctId":"NCT07406048","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Farmaceutica Ltda.","startDate":"2026-01-30","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":396},{"nctId":"NCT07396987","phase":"NA","title":"Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Juan Carlos Cardet","startDate":"2026-02","conditions":"Asthma Attack, Asthma Control, Asthma Exacerbations","enrollment":40},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT05341726","phase":"NA","title":"BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-01-19","conditions":"Asthma","enrollment":400},{"nctId":"NCT04481555","phase":"PHASE4","title":"Eosinophil-guided Reduction of Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2021-06-28","conditions":"COPD, Inhaled Corticosteroid, Azithromycin","enrollment":444},{"nctId":"NCT07351916","phase":"","title":"Remission in Adults With Mild-to-moderate Asthma in Thailand","status":"NOT_YET_RECRUITING","sponsor":"Thammasat University","startDate":"2026-02-01","conditions":"Asthma, Mild-to-moderate Asthma, Asthma Control Level","enrollment":289},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT05607719","phase":"PHASE2","title":"Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-04-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":30},{"nctId":"NCT07315555","phase":"NA","title":"Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-01-01","conditions":"Community Acquired Pneumonia","enrollment":90},{"nctId":"NCT04990167","phase":"PHASE2","title":"Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)","status":"TERMINATED","sponsor":"Nemours Children's Clinic","startDate":"2022-01-01","conditions":"Asthma in Children","enrollment":11},{"nctId":"NCT06422689","phase":"PHASE4","title":"Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-10","conditions":"Asthma","enrollment":1507},{"nctId":"NCT06029595","phase":"PHASE2","title":"Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-26","conditions":"Uncontrolled Asthma","enrollment":517},{"nctId":"NCT07288827","phase":"NA","title":"Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-05-04","conditions":"Primary Ciliary Dyskinesia, Healthy","enrollment":40},{"nctId":"NCT05832437","phase":"NA","title":"BREATHE-Peds Pilot- II III Trial and Post Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2023-05-04","conditions":"Asthma in Children","enrollment":67},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":"Asthma, Asthma Attack, Asthma Exacerbations","enrollment":3200},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT05329194","phase":"PHASE4","title":"Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-04-29","conditions":"Asthma","enrollment":287},{"nctId":"NCT05086432","phase":"NA","title":"Sputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With ILD","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-05-22","conditions":"ILD","enrollment":120},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":60},{"nctId":"NCT05689983","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-01","conditions":"Asthma in Children, Nonadherence, Medication","enrollment":40},{"nctId":"NCT05111262","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-12-16","conditions":"Asthma, Nonadherence, Medication","enrollment":60},{"nctId":"NCT06970080","phase":"PHASE4","title":"Therapeutic Relevance of Abnormal Airway Morphology in Asthma","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-02","conditions":"Asthma","enrollment":242},{"nctId":"NCT05919394","phase":"PHASE4","title":"Triple vs High Dose Inhaled CORticosteroids","status":"WITHDRAWN","sponsor":"Galaxia Empírica","startDate":"2023-06-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT05477108","phase":"PHASE1","title":"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT04643158","phase":"PHASE2","title":"Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT05569421","phase":"PHASE1","title":"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT04053634","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-26","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":689},{"nctId":"NCT06340581","phase":"PHASE1","title":"A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-10-17","conditions":"Healthy","enrollment":""},{"nctId":"NCT06721247","phase":"PHASE2, PHASE3","title":"Oral Intake of Mg in Controlled Asthmatic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2024-11-02","conditions":"Bronchial Asthma","enrollment":166},{"nctId":"NCT06297668","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT05505734","phase":"PHASE3","title":"A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2022-09-02","conditions":"Asthma","enrollment":2516},{"nctId":"NCT01718197","phase":"","title":"Severe Asthma Research Program (SARP)- San Francisco Clinical Site","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-11","conditions":"Asthma","enrollment":151},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT04942483","phase":"","title":"Using Tests in Preschool Children With Wheeze to Determine the Need for Inhaled Corticosteroid Therapy.","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2021-11-17","conditions":"Wheezing","enrollment":118},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT06732141","phase":"NA","title":"Remote Anxiety Management for ICS-resistant Asthma Study","status":"RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2024-12-13","conditions":"Asthma","enrollment":216},{"nctId":"NCT07030881","phase":"NA","title":"Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-06-20","conditions":"Asthma, COPD","enrollment":380},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT03692676","phase":"","title":"Characteristics of Pts Initiating Spiriva Respimat in Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-05","conditions":"Asthma","enrollment":116133},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":"COPD","enrollment":48},{"nctId":"NCT03141424","phase":"PHASE4","title":"Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2022-06-01","conditions":"Asthma","enrollment":20},{"nctId":"NCT06869382","phase":"PHASE4","title":"ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression","status":"COMPLETED","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2023-01-01","conditions":"Asthma Patients","enrollment":26},{"nctId":"NCT05563675","phase":"PHASE4","title":"Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause","status":"COMPLETED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2023-01-27","conditions":"COPD Exacerbation","enrollment":10011},{"nctId":"NCT03134755","phase":"","title":"Stress and Treatment Response in Puerto Rican Children With Asthma","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2018-05-15","conditions":"Asthma in Children","enrollment":249},{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":9},{"nctId":"NCT06772454","phase":"","title":"To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)","status":"RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2023-01-01","conditions":"Lung Cancer Squamous Cell, COPD","enrollment":60},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT05018598","phase":"PHASE4","title":"Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-25","conditions":"Asthma","enrollment":320},{"nctId":"NCT06657066","phase":"PHASE2, PHASE3","title":"EFFECTIVENESS of PROBIOTICS in ADULTS with MODERATE to SEVERE PERSISTENT ASTHMA","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2021-12-06","conditions":"Asthma Patients","enrollment":74},{"nctId":"NCT03788057","phase":"NA","title":"Inflammatory Indices in Predicting the Failure of Inhaled Corticosteroids Reduction in Young Participants With Asthma","status":"COMPLETED","sponsor":"National Institute for Tuberculosis and Lung Diseases, Poland","startDate":"2016-02-01","conditions":"Asthma Chronic","enrollment":58},{"nctId":"NCT06567977","phase":"","title":"TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients","status":"RECRUITING","sponsor":"Chiesi Poland Sp. z o.o.","startDate":"2024-08","conditions":"Asthma","enrollment":60},{"nctId":"NCT05402020","phase":"","title":"Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":17018},{"nctId":"NCT06535087","phase":"","title":"The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","status":"RECRUITING","sponsor":"Wenjing Zhou","startDate":"2024-07-20","conditions":"Pediatric Asthma, Rhinitis, Allergic, Quality of Life","enrollment":600},{"nctId":"NCT05042219","phase":"","title":"Effects of Pulmonary Diseases and Their Treatment on Cardiac Function","status":"RECRUITING","sponsor":"Ayham Daher","startDate":"2022-06-01","conditions":"COPD, Bronchial Asthma, Idiopathic Pulmonary Fibrosis","enrollment":120},{"nctId":"NCT00545844","phase":"PHASE4","title":"Singulair(R) In Asthma And Allergic Rhinitis (0476-383)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04-01","conditions":"Asthma","enrollment":313},{"nctId":"NCT00442559","phase":"PHASE4","title":"Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01","conditions":"Asthma, Allergic Rhinitis","enrollment":191},{"nctId":"NCT05501639","phase":"","title":"Exacerbation Risk in Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-05-14","conditions":"Asthma","enrollment":1899},{"nctId":"NCT02062463","phase":"PHASE3","title":"Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05-28","conditions":"Asthma","enrollment":485},{"nctId":"NCT03907410","phase":"NA","title":"The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2019-09-01","conditions":"Medication Adherence, Asthma in Children","enrollment":125},{"nctId":"NCT05104892","phase":"PHASE2","title":"Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-12-12","conditions":"Asthma","enrollment":196},{"nctId":"NCT03479138","phase":"","title":"Non-Eosinophilic Neutrophilic Asthma","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2018-02-21","conditions":"Neutrophilic Asthma","enrollment":10},{"nctId":"NCT05078021","phase":"","title":"Phenotyping Disease Severity in Asthma","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2022-04-21","conditions":"Asthma","enrollment":60},{"nctId":"NCT03527927","phase":"NA","title":"sTep dOWn Inhalers in the reAl woRlD","status":"COMPLETED","sponsor":"Hywel Dda Health Board","startDate":"2017-05-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":67},{"nctId":"NCT01108627","phase":"PHASE4","title":"Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists","status":"WITHDRAWN","sponsor":"Nemours Children's Clinic","startDate":"2010-10","conditions":"Safety of Long Acting Beta Agnoists","enrollment":""},{"nctId":"NCT04265105","phase":"PHASE2, PHASE3","title":"Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-12-22","conditions":"Asthma","enrollment":18},{"nctId":"NCT03489746","phase":"NA","title":"Steroid Withdrawal Intervention in Fife and Tayside","status":"WITHDRAWN","sponsor":"NHS Tayside","startDate":"2018-05-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT03620747","phase":"PHASE3","title":"Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-30","conditions":"Asthma","enrollment":393},{"nctId":"NCT04677959","phase":"PHASE4","title":"A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2021-02-16","conditions":"Asthma","enrollment":427},{"nctId":"NCT05459805","phase":"NA","title":"Multicenter Clinical Study on the Optimal Treatment Protocol and Outcome of Cough Variant Asthma With Chinese and Western Medicine","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhejiang Chinese Medical University","startDate":"2022-03-01","conditions":"Cough Variant Asthma","enrollment":164},{"nctId":"NCT05689931","phase":"","title":"Blood Leukocyte Profiling in Eosinophilic Type 2 Asthma: Influence of Systemic IL-5 Targeting","status":"UNKNOWN","sponsor":"Region Skane","startDate":"2023-02-01","conditions":"Asthma","enrollment":80},{"nctId":"NCT05553379","phase":"","title":"Vivatmo proTM EU-study: FeNO Monitoring in Asthmatic Patients Responding to ICS Treatment","status":"UNKNOWN","sponsor":"Bosch Healthcare Solutions GmbH","startDate":"2022-03-15","conditions":"Asthma","enrollment":48},{"nctId":"NCT05442307","phase":"NA","title":"Academic Detailing About Asthma","status":"UNKNOWN","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2021-10-06","conditions":"Prescription Pattern","enrollment":360},{"nctId":"NCT01397201","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT03265145","phase":"PHASE4","title":"Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":714},{"nctId":"NCT04450108","phase":"NA","title":"Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients","status":"COMPLETED","sponsor":"Bosch Healthcare Solutions GmbH","startDate":"2020-09-08","conditions":"Asthma, Asthma in Children","enrollment":122},{"nctId":"NCT04172701","phase":"","title":"A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":9284},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT02215122","phase":"PHASE1","title":"Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2013-10","conditions":"Asthma, COPD","enrollment":40},{"nctId":"NCT04876677","phase":"PHASE3","title":"Functional Respiratory Imaging Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-05-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT03207620","phase":"","title":"Interrelation Between Bronchial Asthma and Smoking","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-08-09","conditions":"Bronchial Asthma","enrollment":117},{"nctId":"NCT04206761","phase":"PHASE3","title":"Investigating the Effects of QVM149 on MRI Ventilation Defects","status":"WITHDRAWN","sponsor":"Dr. Grace Parraga","startDate":"2021-12-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT05145894","phase":"","title":"Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device","status":"UNKNOWN","sponsor":"Healthy Networks","startDate":"2021-09-30","conditions":"Asthma, COPD","enrollment":200},{"nctId":"NCT04138758","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"COPD","enrollment":42953},{"nctId":"NCT04184297","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":27190},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT04402515","phase":"","title":"Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2021-10-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE"}],"_approvalHistory":[],"publicationCount":2304,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Treatments prescribed during regular clinical practice"],"phase":"marketed","status":"active","brandName":"Inhaled Corticosteroids (ICs)","genericName":"Inhaled Corticosteroids (ICs)","companyName":"Parc de Salut Mar","companyId":"parc-de-salut-mar","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhaled corticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation. Used for Asthma (mild to moderate persistent), Chronic obstructive pulmonary disease (COPD), Asthma-COPD overlap syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}